Hansa Biopharma publishes Annual Report 2022
Lund, Sweden, March 30, 2023 Hansa Biopharma AB “Hansa” (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced the release of the Annual Report 2022. Søren Tulstrup, President and CEO of Hansa Biopharma, comments: “2022 was a successful year at Hansa, with solid performance and strong progress across the organization. While the global geopolitical and financial environment made 2022 a very challenging year for the biotech sector overall, I am very pleased with the solid performance and strong progress across our R&D and commercial